The PCOS opportunity: a deep dive into this unsolved area of women’s health
No cure, a thin pharmaceutical pipeline and huge unmet need. Here are the innovators solving for this space.
After more than a decade of campaigning work spearheaded by the UK charity Verity and Australia’s Monash University, Polycystic Ovary Syndrome is about to be renamed.
It’s a big deal - for patients, providers and anyone who has worked in the space. Because for years, the name itself has shaped how PCOS is understood, diagnosed and treated - and arguably has contributed to the speed (or lack of) progress.
Described by one patient as ‘misleading, medically outdated and emotionally invalidating’, ‘Polycystic Ovary Syndrome’ has never accurately represented PCOS as a condition. It centres the ovary, it suggests cysts and it reinforces the idea that this is predominantly a reproductive issue.
And while PCOS is a leading cause of infertility - affecting up to 80% of women with the condition - it’s never been the full picture.
PCOS is now more accurately understood as a lifelong metabolic and neuroendocrine condition - not just something that shows up when someone is trying to get pregnant. It’s associated with a 2–3x higher risk of developing type 2 diabetes, significantly increased rates of depression, and a substantially higher risk of cardiovascular disease.
The name change is therefore much more than a ‘rebrand’. It’s going to have positive impacts for innovators, investors and operators. It expands the market beyond fertility into chronic disease, brings new types of players into the space, and helps explain why some of the progress around PCOS has been slow to date - and why that is starting to change
In this FutureFemHealth deep dive we explore some of the big questions in PCOS:
what makes PCOS so complex
is it possible to build a single ‘PCOS solution’ - or whether point solutions will win
why innovation has lagged in this area
who are the companies building in this space
what other drivers might finally shift this market
What we get wrong about PCOS - and why it’s difficult to solve
Speak to any PCOS patient and you’ll likely hear variations on the same story:
“They only really cared when it came to having children — at that point it was IVF.”
“In my 20s I was just put on the pill — the go-to ‘solution’ for PCOS.”
“I’ve been left experimenting with nutrition, exercise and supplements to try to manage skin and weight.”
“I was told my symptoms were ‘normal’, or just about my weight - and I felt dismissed when I tried to push for answers.”
Part of the problem is that PCOS does not present in one clear, consistent way.
It can show up as fertility issues, irregular cycles, acne, weight changes, hirsutism, hair loss, insulin resistance and mental health challenges. Diagnosis - most commonly based on the Rotterdam criteria relies on identifying a combination of symptoms rather than a single underlying cause.
Despite affecting around 10-13% of women globally, it remains underdiagnosed, with many women navigating symptoms for years before receiving answers.
At the same time, PCOS cuts across multiple healthcare categories: fertility, metabolic disease, cardiometabolic risk and mental health. Then in practice it is still most often framed and treated as a reproductive condition, or worse, a ‘cosmetic’ one (weight gain and acne).
This is the mismatch.
Because emerging research now points to PCOS as an early-life risk profile with lifelong implications, where earlier intervention could materially change long-term outcomes.
In other words, PCOS often begins earlier - and runs deeper - than the way we currently treat it.
This is what makes PCOS so difficult to solve.
PCOS is not a single, clearly defined disease. Increasingly researchers and clinicians argue that what we call PCOS may be a set of related - and potentially distinct - conditions involving overlapping systems such as insulin resistance, neuroendocrine disruption (including LH/FSH signalling), androgen excess and chronic inflammation.
For some patients this results primarily in infertility, for others dermatological symptoms such as acne or hirsutism, and many, they may show signs of metabolic dysfunction with long-term health implications.
So, if different PCOS subtypes are driven by fundamentally different mechanisms - then a single therapy is unlikely to work for everyone.
But complex science is only part of the story.
The incentives bottleneck
The other complexity for PCOS care - and arguably the most important one - is incentives.
Clinical understanding is starting to catch up. International PCOS guidelines increasingly reflect the condition’s metabolic, reproductive and pyschological dimensions. They are well-established and adoption is expanding (the UK’s National Institute for Health and Care Excellence will adopt them soon).
But all this still doesn’t translate into aligned incentives.
For decades, most PCOS patients have been managed using inexpensive, widely available drugs.
Typically that means:
oral contraceptives to regulate cycles
medications such as metformin to address insulin resistance
anti-androgens to manage symptoms like acne and excess hair growth.
Fertility treatments are then introduced when pregnancy becomes a priority.
These options can help with symptoms, but they do not change the underlying course of the condition.
This creates a difficult starting point for innovation.
When existing treatments are cheap, widely available and ‘good enough’ for symptom management (according to the system, not patients), any new therapy has to clear a much higher bar - not just clinically, but economically.
At the same time, many of the most visible symptoms of PCOS - such as infertility or excess hair growth — are often framed within healthcare systems as lifestyle or elective concerns rather than part of a chronic metabolic condition.
So all of this shapes how treatments are reimbursed, how research is prioritised and ultimately where investment flows.
In practice, this is reinforced by how PCOS is coded and paid for - particularly in systems like the US. Rather than being recognised and reimbursed as a distinct, lifelong condition, PCOS is often broken apart into its downstream effects: fertility treatment, diabetes risk, cardiovascular health, or mental health support.
That fragmentation makes the condition harder to “see” as a single disease entity within the system. And when a condition is not clearly defined in coding and reimbursement terms, it becomes much harder to build pathways for earlier intervention - or to justify investment in treatments that aim to change its long-term trajectory rather than manage its symptoms.
So, for many companies innovating in the space, the challenge is not just scientific but economic. How do you build a clear, defensible value story when the condition itself is heterogeneous, outcomes play out over the long-term, and existing treatments - however imperfect - are inexpensive?
Without strong health economic evidence showing how earlier or more targeted interventions reduce later costs, PCOS can appear difficult to underwrite compared to more clearly defined disease areas.
This is not just a theoretical challenge. A 2026 white paper from the Artemis Women’s Health Foundation describes a structural stalemate across the system — where incentives across payers, regulators and industry are not aligned to support new therapies. As a result, the drugs pipeline for PCOS is incredibly thin.
Meanwhile, the fertility sector has built a large and profitable industry around assisted reproduction. For many patients, IVF becomes the default escalation pathway - this reinforces a model focused on late-stage intervention rather than early disease modification.
There are early signs of the scale of this mismatch. In the US alone, direct healthcare costs linked to PCOS are estimated to exceed $15 billion annually. And yet no therapies are approved specifically to treat its underlying causes.
In effect, the system is currently paying significant amounts to treat the consequences of PCOS - but not to change its trajectory.
This is the paradox at the centre of the PCOS market.
In summary, no single stakeholder is fully incentivised to solve PCOS - despite the fact it carries long term risks including diabetes, cardiovascular disease and endometrial cancer. And alongside this, the condition also generates billions in healthcare costs through infertility care, metabolic disease and associated complications.
These costs are distributed across fertility clinics, primary care, endocrinology, and long-term chronic disease management - often coded, funded and managed as separate issues across different budgets, systems and time horizons.
And when a condition isn’t fully owned by any one part of the system, the incentives to invest in long-term, disease-modifying solutions remain weak.
Now, it’s exactly this gap — between biological complexity, economic incentives and patient need — where a new generation of innovators is beginning to focus.
The forces driving new innovation
There’s a number of forces which are driving new innovation in the PCOS space:
patient-driven entrepreneurship - a number of founders in the space have experienced PCOS themselves and have a deep understanding of what gaps to fill and how to speak to patients in a way that actually resonates.
a white space left by the lack of a pharmaceutical drugs pipeline. As discussed earlier, PCOS has historically relied on repurposed medications such as oral contraceptives, metformin and fertility drugs. While these treatments can alleviate symptoms, they do not address the underlying condition - leaving significant white space for new approaches.
evolving science - PCOS is now being understood not as a single condition, but as a spectrum of metabolic, neuroendocrine and hormonal patterns. As large-scale patient datasets emerge, researchers are beginning to reveal distinct biological subtypes.
New insights into the biology of PCOS - emerging research is reshaping how scientists understand androgen excess, a key driver of symptoms. For example, a group of hormones known as 11-oxygenated androgens, produced mainly by the adrenal glands, may play a larger role than previously thought.
Taken together these shifts are starting to change how PCOS is understood and where innovation is beginning to take hold. This all shows up in how the market is evolving.
Mapping the emerging PCOS innovation landscape
Globally, estimates of the PCOS market vary around $4.79 billion in 2024, with forecasts pointing to steady mid-single-digit growth through the early 2030s. Yet most of that revenue still comes from repurposed medications — oral contraceptives, insulin-sensitising drugs such as metformin and fertility treatments.
The companies and technologies emerging around PCOS suggest that innovation is forming across several distinct layers of the ecosystem.
Rather than being driven by a single breakthrough drug, the space is evolving across therapeutics, care models, digital infrastructure, supplements and diagnostics.
This pattern reflects the unusual structure of the market itself.
In other words, the current market remains dominated by symptom management, while much of the real innovation is happening around the edges. Rather than a single category, PCOS is emerging as a multi-layered ecosystem - spanning therapeutics, care delivery, consumer health, and data infrastructure.
Several areas of activity are beginning to emerge.
In this next section we map out the current market in six groupings, before turning to explore what could drive forward the PCOS market in the future.
